Home Newsfeeds Apple Supplier Pegatron Denies Reports of China Blocking Shipments

News

Apple Supplier Pegatron Denies Reports of China Blocking Shipments

-MacRumors https://www.macrumors.com/2022/08/05/apple-supplier-denies-china-blocking-shipments/

byCharles Gross

August 5, 2022

1 minute read

-MacRumors

https://www.macrumors.com/2022/08/05/apple-supplier-denies-china-blocking-shipments/

Analyst Upgrades This Radiology Stock, Expects Promising 2023 Ahead

By Vandana Singh

March 3, 2:38 PM

Raymond James upgraded Radnet Inc (NASDAQ:RDNT) from Market Perform to Outperform and a price target of $30 following 4Q22 results that came in…

RDNT

AMD To Rally Over 26%? Here Are 10 Other Analyst Forecasts For Wednesday

By Lisa Levin

February 1, 9:10 AM

Credit Suisse boosted the price target for Mondelez International, Inc. (NASDAQ: MDLZ) from $70 to $76. Credit Suisse analyst Robert Moskow maintained an Outperform rating. Mondelez shares rose 1.8% to $66.61 in pre-market trading.

AMD

P/E Ratio Insights for Orange

By Benzinga Insights

January 11, 3:00 PM

In the current market session, Orange Inc. (NYSE:ORAN) share price is at $11.68, after a 1.04% increase. Moreover,…

ORAN

CNS Pharmaceuticals Receives Approval From Competent Authority And Central Ethics Committee In Italy For Potentially Pivotal Global Trial Evaluating Berubicin For The Treatment Of GBM

By Happy Mohamed

April 6, 9:08 AM

Continued advancement of global patient enrollment with approvals and site activations in the U.S., Switzerland, France, Spain and Italy Enrollment continuing to progress toward an interim analysis expected in

CNSP

Apple Supplier Pegatron Denies Reports of China Blocking Shipments

Related Posts

Analyst Upgrades This Radiology Stock, Expects Promising 2023 Ahead

AMD To Rally Over 26%? Here Are 10 Other Analyst Forecasts For Wednesday

P/E Ratio Insights for Orange

CNS Pharmaceuticals Receives Approval From Competent Authority And Central Ethics Committee In Italy For Potentially Pivotal Global Trial Evaluating Berubicin For The Treatment Of GBM